Tandem Diabetes Care Announces Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance
Non-GAAP operating loss(1) totaled $22.5 million, or negative 11 percent of sales, compared to $2.4 million or negative 1 percent of sales.
- Non-GAAP operating loss(1) totaled $22.5 million, or negative 11 percent of sales, compared to $2.4 million or negative 1 percent of sales.
- Adjusted EBITDA(1) was $4.3 million, or 2 percent of sales, compared to $25.7 million, or 11 percent of sales.
- Net income (loss): GAAP net loss was $30.0 million, compared to net loss of $15.9 million.
- Sales: In the United States, GAAP sales include a $25.1 million deferral relating to Tandem Choice, compared to a deferral of $3.5 million.